CorMedix Inc. (FRA:19KA)
Germany · Delayed Price · Currency is EUR | Market Cap | 490.77M +21.0% |
| Revenue (ttm) | 265.48M +617.0% |
| Net Income | 138.03M |
| EPS | 1.74 |
| Shares Out | n/a |
| PE Ratio | 3.56 |
| Forward PE | 7.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 10 |
| Open | 6.09 |
| Previous Close | 6.16 |
| Day's Range | 6.09 - 6.09 |
| 52-Week Range | 5.20 - 14.60 |
| Beta | n/a |
| RSI | 55.49 |
| Earnings Date | May 11, 2026 |
About CorMedix
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]
News
CorMedix to Participate in Needham Virtual Healthcare Conference
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threateni...
CorMedix stock drops after earnings: is this dip a buy before key catalyst?
CorMedix (NASDAQ: CRMD) opened meaningfully down on March 5th after reporting a massive swing to profitability but reaffirming 2026 guidance that failed to impress shareholders. The biopharmaceutical ...
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Sched...
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr...
CorMedix to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics Announces Share Repurchase Program
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
Why is CorMedix stock crashing today: is it worth buying on the dip?
Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn't sitting well with shareholders, prima...
CorMedix Therapeutics Announces Leadership and Board Updates
BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 mi...
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of...
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance R...
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of CorMedix Inc. (NASDAQ: CRMD) breached their fiduciary duties to sha...
CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why
Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partn...
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒ ‒ Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ‒ ‒ Raising FY 2025 Pro Forma Net Revenue Guidance to at least ...
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant -
CorMedix Announces Strategic Minority Investment in Talphera
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for lif...
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million...
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue...
CorMedix to Buy Melinta Therapeutics for $300 Million
The buyer said the deal adds six marketed infectious-disease products to its offerings.